Drugmaker Aspen Pharmacare says it will raise up to R1.9bn by selling a portfolio of products in Australia and New Zealand to US group Mylan. Aspen, whose shares have more than halved since September 2018 on concerns that the group has too much debt, said it will use the proceeds to reduce gearing. In December, Aspen entered into a distribution agreement with Mylan subsidiary Alphapharm regarding the portfolio of prescription and over-the-counter products sold mainly in Australia and New Zealand. Mylan was also given an option to buy the portfolio. Aspen said on Monday Mylan will buy the portfolio for a maximum consideration of 188-million Australian dollar, of which 93-million Australian dollar is payable by the end of May, 30-million Australian dollar is due in January 2020, and up to 65-million Australian dollar is payable in September 2020. The value of the last payment is partially contingent on Aspen satisfying certain conditions. “This divestment is in line with the group...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now